Related Experiment Video

Updated: Mar 17, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

15.3K

Glutathione-S-transferases and Chemotherapy Resistance of Hodgkin's Lymphoma Cell Lines

Toralf Bernig1, Stephanie Ritz1, Grit Brodt1

  • 1Department of Pediatrics, Martin Luther University Halle-Wittenberg, Halle, Germany.

Anticancer Research
|July 29, 2016
PubMed
Abstract

Insights

Glutathione-S-transferases (GSTs) contribute to chemoresistance in Hodgkin

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glutathione-S-transferases (GSTs) are implicated in tumor multidrug resistance, drug detoxification, and apoptosis regulation.
  • Understanding GST involvement in Hodgkin's lymphoma (HL) is crucial for overcoming treatment resistance.

Purpose of the Study:

  • To investigate the role of GSTs in the apoptosis of Hodgkin's lymphoma (HL) cells.
  • To evaluate the potential of GST inhibitors in overcoming chemoresistance in HL.

Main Methods:

  • Assessed GST isoform expression in HL cell lines using DNA microarray and quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
  • Evaluated the in vitro effect of the GST inhibitor ethacrynic acid (EA) on HL cell survival and chemosensitivity.

Main Results:

  • Higher expression of GST isoforms was observed in chemoresistant HL cells, suggesting a role in chemoresistance.
  • Ethacrynic acid (EA) significantly enhanced cisplatin efficacy in GST-expressing chemoresistant HL cells.

Conclusions:

  • GSTs are associated with chemoresistance in Hodgkin's lymphoma.
  • Combined therapy with chemotherapy and GST inhibitors like EA shows promise for treating chemoresistant HL.
Keywords:
Hodgkin's lymphomachemotherapyethacrynic acidglutathione-S-transferases

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
95